Q32 Bio reports Q3 2026 results and advances bempikibart toward Phase 3
Q32 Bio announced third‑quarter 2026 financial results and presented additional 36‑week and 16‑week off‑drug data from Part B of its SIGNAL‑AA Phase 2a trial of bempikibart in severe alopecia areata. The trial showed a mean 35.3% reduction in SALT scores and 40% of patients achieving a SALT‑20 response in the modified intent‑to‑treat analysis. The company plans to start a registration‑directed program for severe or very severe AA in the first half of 2027 and appointed a new chief medical officer and chief development officer.
Why it matters
The company says its $289.6 million cash balance will fund operations through topline Phase 3 results from the planned registration‑directed program. The net loss of $8.9 million reflects higher R&D and G&A spending as the trial progresses, indicating increased cash burn before potential product approval.
Key facts
- 1Cash and cash equivalents were $289.6 million as of September 30, 2026. prnewswire.com
- 2Net loss for Q3 2026 was $8.9 million, or $0.26 per share. tradingview.com
- 3Research and development expenses increased to $5.1 million. tradingview.com
- 4General and administrative expenses rose to $5.5 million. tradingview.com
- 5In Part B, bempikibart produced a mean 35.3% reduction in SALT score from baseline in the prespecified modified intent‑to‑treat analysis. prnewswire.com
- 640.0% of patients achieved a SALT‑20 response in the modified intent‑to‑treat analysis. prnewswire.com
Summary written by AlphAI AI Desk from 5 of 5 sources. Not investment advice. Figures are as stated by the linked sources.